https://scholars.lib.ntu.edu.tw/handle/123456789/526879
標題: | Risk of gastrointestinal perforation in patients taking oral fluoroquinolone therapy: An analysis of nationally representative cohort | 作者: | Hsu S.-C. Chang S.-S. Lee M.-T.G. Lee S.-H. Tsai Y.-W. Lin S.-C. Chen S.-T. Weng Y.-C. Porta L. Wu J.-Y. CHIEN-CHANG LEE |
公開日期: | 2017 | 卷: | 12 | 期: | 9 | 起(迄)頁: | e0183813 | 來源出版物: | PLoS ONE | 摘要: | Background: Fluoroquinolone is a commonly prescribed antimicrobial agent, and up to 20% of its users registers adverse gastroenterological symptoms. We aimed to evaluate the association between use of fluoroquinolone and gastrointestinal tract perforation. Methods: We conducted a nested case-control study on a national health insurance claims database between 1998 and 2011. The use of fluoroquinolones was classified into current (< 60 days), past (61–365 days prior to the index date) and any prior year use of fluoroquinolones. We used the conditional logistic regression model to estimate rate ratios (RRs), adjusting or matching by a disease risk score (DRS). Results: We identified a cohort of 17,510 individuals diagnosed with gastrointestinal perforation and matched them to 1,751,000 controls. Current use of fluoroquinolone was associated with the greatest increase in risk of gastrointestinal perforations after DRS score adjustment (RR, 1.90; 95% CI, 1.62–2.22). The risk of gastrointestinal perforation was attenuated for past (RR, 1.33; 95% CI, 1.20–1.47) and any prior year use (RR, 1.46; 95% CI, 1.34–1.59). To gain insights into whether the observed association can be explained by unmeasured confounder, we compared the risk of gastrointestinal perforation between fluoroquinolone and macrolide. Use of macrolide, an active comparator, was not associated with a significant increased risk of gastrointestinal perforation (RR, 1.11, 95%CI, 0.15–7.99). Sensitivity analysis focusing on perforation requiring in-hospital procedures also demonstrated an increased risk associated with current use. To mitigate selection bias, we have also excluded people who have never used fluoroquinolone before or people with infectious colitis, enteritis or gastroenteritis. In both of the analysis, a higher risk of gastrointestinal perforation was still associated with the use of fluoroquinolone. Conclusions: We found that use of fluoroquinolones was associated with a non-negligible increased risk of gastrointestinal perforation, and physicians should be aware of this possible association. ? 2017 Hsu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/526879 | ISSN: | 1932-6203 | DOI: | 10.1371/journal.pone.0183813 | SDG/關鍵字: | macrolide; quinolone derivative; antiinfective agent; quinolone derivative; adult; antimicrobial therapy; Article; case control study; cohort analysis; colitis; comparative study; controlled study; digestive system perforation; disease association; disease risk score; drug use; enteritis; female; gastroenteritis; health care utilization; hospital admission; human; longitudinal study; major clinical study; male; middle aged; national health insurance; outcome assessment; prevalence; risk assessment; risk factor; selection bias; sensitivity analysis; treatment duration; aged; chemically induced; drug effects; gastrointestinal disease; intestine; intestine perforation; oral drug administration; pathology; regression analysis; risk factor; sensitivity and specificity; Taiwan; treatment outcome; Administration, Oral; Aged; Anti-Bacterial Agents; Case-Control Studies; Cohort Studies; Female; Fluoroquinolones; Gastrointestinal Diseases; Humans; Intestinal Perforation; Intestines; Male; Middle Aged; Regression Analysis; Risk Assessment; Risk Factors; Sensitivity and Specificity; Taiwan; Treatment Outcome |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。